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LC3Current research on Parkinson's disease (PD) pathogenesis requires relevant animalmodels thatmimic the grad-
ual and progressive development of neuronal dysfunction and degeneration that characterizes the disease. Poly-
morphisms in engrailed 1 (En1), a homeobox transcription factor that is crucial for both the development and
survival ofmesencephalic dopaminergic neurons, are associatedwith sporadic PD. This suggests that En1mutant
mice might be a promising candidate PDmodel. Indeed, a mouse that lacks one En1 allele exhibits decreasedmi-
tochondrial complex I activity and progressive midbrain dopamine neuron degeneration in adulthood, both fea-
tures associatedwith PD.We aimed to further characterize the disease-like phenotype of these En1+/−micewith
a focus on early neurodegenerative changes that can be utilized to score efﬁcacy of future diseasemodifying stud-
ies.Weobserved early terminal defects in the dopaminergic nigrostriatal pathway in En1+/−mice. Severalweeks
before a signiﬁcant loss of dopaminergic neurons in the substantia nigra could be detected, we found that striatal
terminals expressing high levels of dopaminergic neuron markers TH, VMAT2, and DAT were dystrophic and
swollen. Using transmission electron microscopy, we identiﬁed electron dense bodies consistent with abnormal
autophagic vacuoles in these terminal swellings. In line with these ﬁndings, we detected an up-regulation of the
mTORpathway, concurrentwith a downregulation of the autophagicmarker LC3B, in ventralmidbrain andnigral
dopaminergic neurons of the En1+/−mice. This supports the notion that autophagic protein degradation is re-
duced in the absence of one En1 allele. We imaged the nigrostriatal pathway using the CLARITY technique and
observed many fragmented axons in the medial forebrain bundle of the En1+/− mice, consistent with axonal
maintenance failure. Using in vivo electrochemistry, we found that nigrostriatal terminals in the dorsal striatum
were severely deﬁcient in dopamine release and reuptake. Our ﬁndings support a progressive retrograde degen-
eration of En1+/− nigrostriatal neurons, akin to what is suggested to occur in PD. We suggest that using the
En1+/−mice as a model will provide further key insights into PD pathogenesis, and propose that axon terminal
integrity and function can be utilized to estimate dopaminergic neuron health and efﬁcacy of experimental PD
therapies.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).vai.org, 333 Bostwick Ave. N.E.,
34 5129.
ect.com).
. This is an open access article underIntroduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder
affecting multiple neuronal systems. Mitochondrial dysfunction, altered
autophagy, and aggregation of α-synuclein are among the pathogenic
events suggested to play key roles in the disorder (Sanchez-Perez et al.,the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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sion and degeneration of dopaminergic neurons in the substantia nigra
are particularly prominent in PD and are believed to underlie the classic
motor dysfunctions. Recent studies of patient autopsymaterial have sug-
gested that the disease process is initiated at the level of the dopamine
terminals in the striatum and that the neuronal death, i.e. loss of cell bod-
ies in the substantia nigra occurs later (Burke and O'Malley, 2013;
Kordower et al, 2013). Several rodent PD models have been used to ex-
plore different aspects of dopamine neuron degeneration (Bezard et al.,
2013; Blesa et al., 2012). Chieﬂy among them are the toxin-basedmodels,
e.g. injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
or 6-hydroxydopamine (6-OHDA), which cause failure of mitochondrial
respiration and relatively rapid death of the dopaminergic neurons
(Bezard et al., 2013). However, these models do not faithfully recreate
the protracted degeneration of dopaminergic neurons suggested to
occur in PD, which seems to start in the dopaminergic striatal terminals
and culminate in the death of nigral neurons months to years later. We
expect the models that mimic these features to be more relevant to PD.
Recent genetic analyses have implicated a human gene called en-
grailed1 (En1) in the pathogenesis of PD, reporting that a polymorphism
of En1might tentatively be associated with increased PD susceptibility
(Fuchs et al., 2009). The En1 gene encodes a protein expressed both in
developing and mature dopaminergic neurons (Le Pen et al., 2008;
Sonnier et al., 2007). En1 is also involved in axon guidance (Brunet
et al., 2005;Wizenmann et al., 2009), and controls axonal maintenance
by regulating axonal translation, axonal transport, and mitochondrial
function in the axon of retinal ganglion cells (Yoon et al., 2012). Deletion
of the En1 gene inmice causes speciﬁc changes in themidbrain dopami-
nergic neurons. Homozygous deletion of the gene (En1−/−) can result in
total perinatal loss of dopaminergic neurons, various developmental
defects, and death at birth (Wurst et al., 1994). Unlike En1−/− mice,
animals lacking one En1 allele (En1+/−) are viable and born with a
normal number of dopaminergic neurons in the substantia nigra. But
within 6 weeks after birth, the En1+/− mice exhibit early signs of
substantia nigra dopamine neuron degeneration. This is coupled with
the depletion of striatal dopamine and motor dysfunction, which take
months to fully develop (Sonnier et al., 2007). Furthermore, there is a
decreased activity of the mitochondrial complex I in En1+/− dopami-
nergic neurons (Alvarez-Fischer et al., 2011). Infusion of En1 protein
protects the dopaminergic neurons against mitochondrial toxins by en-
hancing the translation of mitochondrial complex I proteins (Alvarez-
Fischer et al., 2011). In sum, the En1+/− mouse model recapitulates
the key features of the slow progressive human PD pathogenesis, and
is therefore an interesting model in which to evaluate the potential
disease-modifying therapies. In the present study, we aimed to further
characterize the neurodegenerative events in En1+/− mice with a
focus on early changes that can be utilized to score efﬁcacy when
evaluating experimental therapies. Here we report that En1+/− dopa-
minergic neurons display axono-pathology several weeks to months
before dopaminergic neuron death occurs, and that defective autophagy
is likely to play a role in the degenerative process.
Results
Progressive degeneration of dopaminergic neurons in En1+/−mice
We ﬁrst set out to validate our transgenic mouse lines by analyzing
the proper localization of dopamine neuronal markers. Mice heterozy-
gous for En1 expressed the knock-in gene LacZ in the En1 locus. Thus,
we used expression of the β-galactosidase (β-gal) protein as a reporter
for En1-lacking cells in the En1+/−mutant mice. We found that the En1
locus was still active in adult mice, resulting in β-gal protein expression
in the nigral tyrosine hydroxylase (TH)-positive dopaminergic neurons
of the En1+/−mice. The wild-type (WT) mice, in contrast, did not ex-
press β-gal (Fig. 1A). We also used immunohistochemistry with an an-
tibody that recognizes En1 (and its homolog En2), to conﬁrm that Enproteins were expressed in nigral dopaminergic neurons during adult-
hood (Fig. 1B). We used a double mutant dopamine neuron reporter
line to facilitate monitoring of dopamine cell morphology and integrity
by crossingWT and En1+/−mice to a reporter mouse expressing green
ﬂuorescent protein (GFP) under control of the TH promoter (Sawamoto
et al., 2001). As expected, the majority of TH-positive cells in the mid-
brain expressed GFP in these mice (Fig. 1C).
To evaluate the effect of En1 knockdown on the survival of midbrain
dopaminergic neurons, we performed stereological counts of TH-
immunopositive neurons in the substantia nigra of En1+/− and control
WT littermates at various ages (4, 16, and 24 weeks) (Fig. 2A). In
agreement with a previous report (Sonnier et al., 2007), we ob-
served no difference in the number of TH-positive nigral neurons
between the groups at 4 weeks, but the number of TH neurons
was signiﬁcantly reduced in the En1+/− mice at 16 weeks (18%)
and 24 weeks (40%) (Fig. 2B). To test whether loss of TH neuron number
progressively increased with age, we performed a two-factor ANOVA
analysis that revealed signiﬁcant genotype (F(1,36) = 62.03,
p b 0.0001), age (F(2,36) = 15.90, p b 0.0001) and interaction effects
(F(2,36) = 24.22, p b 0.0001). Additionally, the TH level in individually-
sampled dopaminergic neurons was not different between the WT and
En1+/−mice (data not shown, Student's t-test, p N 0.05) at 4 weeks of
age, indicating that TH downregulation is not evident at this young age.
These results demonstrate that the En1+/−mice are born with a normal
number of dopaminergic neurons, and display an age-dependent, slow,
progressive loss of TH-positive cells in the substantia nigra.
Progressive reduction of markers of dopamine neuron function in the
nigrostriatal pathway of En1+/− mice
We performed an immunoblot analysis on midbrain tissues to
monitor if TH protein levels mirrored the progressive loss of TH-
positive neurons. We found that the TH levels in the En1+/− mice
at 4, 16, and 24 weeks of age were 17–44% lower than those of
theWTmice (Fig. 2D). A two-factor ANOVA analysis revealed signiﬁcant
genotype (F(1,30) = 116.5, p b 0.0001) and age (F(2, 30) = 7.448,
p = 0.0024) effects, as well as genotype by age interaction (F
(2,30) = 6.874, p = 0.0035). Tukey's pairwise comparisons revealed
signiﬁcant differences between En1+/− 4 week- and 16 week-groups
(p b 0.05), En1+/− 4 week- and 24 week-groups (p b 0.001), but not
the En1+/− 16week- and 24 week-groups. Consistent with this decline,
we found that TH was reduced by 19–26% in the striatum at the same
ages (Figs. 3B and C). ANOVA results indicated no age effect (F(1,
31) = 1.12, p = 0.3392) on striatal TH levels in En1+/−mice. We also
assayed the levels of dopamine transporter (DAT) in the striatumby im-
munoblotting and found that DAT was 22–50% lower in the En1+/−
mice at those ages (Figs. 3B and D). A two-factor ANOVA revealed a
main effect of genotype, indicating that DAT is decreased in the En1+/−
mice (Fig. 3D). We then used HPLC to analyze striatal levels of dopamine
and its metabolite 3,4-dihydroxyphenylacetic acid (DOPAC), speciﬁcally
in the caudate and putamen region (Fig. 3A). At 4 weeks of age, the dopa-
mine level in the striatum of the En1+/−micewas 27% lower than that in
WT controls, and it was 46% lower by 24 weeks (Fig. 3E). The levels of
DOPAC in the En1+/− mice were not signiﬁcantly different from those
\of controls at 4 weeks of age, but by 24 weeks they were reduced by
39% (Fig. 3F). The ratio between the levels of dopamine and DOPAC
showed an increase of 1.45-fold in the striatum of 4-week-old En1+/−
mice relative toWTanimals, indicating an increase in dopamine turnover,
but there was no difference between the 24-week-old En1+/− and WT
mice (Fig. 3G).
Early signs of nigrostriatal dopaminergic degeneration in axon terminals in
the En1+/− mice
As described above, we found no reduction in the number of TH-
immunoreactive nigral neurons in the En1+/−mice at 4 weeks of age,
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Fig. 2. Progressive loss of TH expression in the ventral midbrain of En1+/−mice. TH expression in themidbrain of 4-, 16-, and 24-week-old En1+/− andWTmice was analyzed by immu-
nohistochemistry (A), stereology (B), and immunoblotting (C, D). A, Representative images of DAB TH staining of substantia nigra, in brain sections used to perform stereological cell
counts. B, Stereological estimation of the number of TH-positive cells in the substantia nigra. Data represent means ± SEM for each group (n= 7 at 4 weeks; n = 6–7 for 16 weeks;
n= 7–8 for 24 weeks). C, TH levels in ventral midbrain lysates were analyzed by SDS-PAGE and immunoblotting was performed in duplicate (n= 6 per group). β-Actin was used as
an internal loading control. Representative images show three independent WT and En1+/− samples. D, Graph represents mean ± SEM ratios of TH band density to β-Actin. Two-factor
ANOVA revealed age and genotype effects and showed that the level of intracellular TH progressively decreased in midbrain region of 4-week-, 16-week- and 24-week-old En1+/−mice
relative to WT mice (**p b 0.01; ***p b 0.001).
73U. Nordström et al. / Neurobiology of Disease 73 (2015) 70–82but TH and dopaminewere all decreased in the En1+/− striatum by this
time. This led us to consider the possibility that the degeneration of
nigrostriatal neurons begins at the level of the striatal terminals in the
En1+/−mice. Thus, we ﬂuorescently labeled sections through the stria-
tum of the En1+/− mice and TH–GFP;En1+/− mice and monitored
striatal dopamine axon terminals in confocal stacks. In striatum sections
from thesemicewe found abnormal TH andGFP co-labeled proﬁles that
appeared to be spheroidal dystrophic terminals of nigrostriatal neurons.
We did not observe such spheroids in WT mice (Fig. 4A). The axonal
spheroids were also immunoreactive for vesicular monoamine trans-
porter 2 (VMAT2) and DAT (Figs. 4B–D). This suggests that the dystro-
phic terminals belong to dopamine neurons that still are capable
of expressing two key proteins known to eventually be depleted in
degenerating dopaminergic neurons (Kordower et al., 2013). We did
not detect the spheroids in the striatum of the En1+/−mice at postnatal
day 3. A few spheroids could be detected as early as postnatal day 8 and
our quantitative analysis revealed that the density of abnormal
spheroids in the striatum progressively increased from 8 days,
through 4 weeks and to 24 weeks of age (A two-factor ANOVA anal-
ysis revealed signiﬁcant genotype (F(1,23) = 4327, P b 0.0001) and
age (F(2,23) = 216.4, P b 0.0001) effects, as well as genotype by age
interaction F(2,23) = 924, P b 0.0001) (Fig. 4E). To gain further in-
sight into the nature of the dystrophic En1+/− striatal terminals,Fig. 1. En1 expression in adult TH-positive dopaminergic neurons in the substantia nigra. A, Ima
and β-gal immunostaining. Analysis revealed expression of β-gal in the nigral TH-positive cells
ysis revealed β-gal in the majority of TH-positive cells in the substantia nigra. B, Double labelin
minergic neurons and showed that En proteins aremainly located to nucleus in TH-positive cells
visualized in sections immunolabeled for TH. The GFP is expressed under the control of the TH p
Scale bars: A, B (10×), and C, 50 μm. Scale bar B (40×), 10 μm.we performed ultrastructural analysis on 1 mm3 blocks of dorsal
striatum from the 8-week-old mice. We observed enlarged axonal
proﬁles displaying accumulations of mitochondria and electron-
dense vacuoles in the En1+/− mice (Figs. 4F–G), suggesting a dis-
turbed autophagic process. We did not observe such axonal proﬁles
in electron micrographs from WT mice. In one En1+/− mouse, we
measured the volume of 23 enlarged axonal proﬁles, which ranged
from 1 μm3 to 92 μm3 (mean ± SEM = 25.2 ± 5.2 μm3), which is
2–200 times the size of a normal nigrostriatal dopamine neuron ter-
minal (Pickel et al., 1981). We hypothesized that these large axonal
spheroids are indicative of axonal degeneration. To further investi-
gate an ongoing dopamine axonal degeneration in the nigrostriatal
pathway of the En1+/−mice, we monitored dopamine axonal integ-
rity in the median forebrain bundle in sagittal sections through
8-week-old brains. Indeed, we found that the TH-immunoreactive
axons in the median forebrain bundle were frequently swollen and
appeared fragmented (Fig. 4H). By applying the CLARITY technique on
1 mm-thick brain sagittal sections, we obtained a three-dimensional
view of the pathological TH-positive ﬁbers in the median forebrain
bundle of 32-week-old WT and En1+/−mice. We observed numerous
swollen and fragmented axons in the mutant mice (Fig. 4I and Supple-
mentary videos 1–2), indicating ongoing axonal degeneration in the
nigrostriatal pathway.ges display substantia nigra of 8-week-oldWT and En1LacZ (En1+/−) mice processed for TH
in En1 heterozygote mice in which the LacZ genewas introduced into one En1 allele. Anal-
g of TH and En1/2 in 5-month-old WTmice conﬁrmed the expression of En in adult dopa-
. C, Validation of the Swiss OF1WT;TH–GFP and En1+/−; TH–GFPmouse lines. Native GFP is
romoter and is present in the majority of the TH-positive neurons of the substantia nigra.
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Fig. 3. Gradual loss of TH and DAT in the striatum of En1+/−mice. A, Drawing depicts the dorsal striatum containing the caudate and putamen regions dissected, and used for immuno-
blotting and HPLC analysis. B, The TH, DAT, and β-Actin protein levels were monitored in lysates prepared from striata of 4-week, 16-week, and 24-week-old En1+/− and WTmice. The
image shows three independent striata homogenate samples per group. C, D, The TH andDAT bands on immunoblots were quantiﬁed (n=6 individual samples per group), normalized to
β-Actin and presented as percentages ofmean±SEM. C, The TH levelswere signiﬁcantly reduced in all En1+/−mice (**pb 0.01; ***pb 0.001; ****p b 0.0001). D, TheDATprotein levelwas
also reduced in the En1+/− samples at all ages. E, Dopamine content in the striatum (caudate and putamen regions) of 4- and 24-week-oldWT and En1+/−mice asmeasured by HPLC and
presented as percentage ofWT values. Signiﬁcant decreases in dopamine levels in En1+/− groups were validated by Student's t-test (**p b 0.01). F, HPLC data for DOPAC levels; signiﬁcant
decreases are marked (*p b 0.05). G, Ratio of DOPAC to dopamine (values normalized to WT) and signiﬁcant increase is shown (*p b 0.05).
74 U. Nordström et al. / Neurobiology of Disease 73 (2015) 70–82Up-regulation of the mTOR signaling pathway and reduction in the
autophagic marker LC3B in the En1+/−mice
Autophagy and mTOR-regulated autophagy pathways have been
implicated in numerous models of neurodegeneration (Pan et al.,
2008; Son et al., 2012; Yamamoto and Yue, 2014). After observing an
accumulation of numerous electron-dense autophagic vacuoles in the
terminal spheroids, we hypothesized a possible alteration of mTOR
signaling in the En1+/− dopamine neurons. We analyzed protein levels
of mTOR signaling markers in the ventral midbrain of 16-week-old WT
and the En1+/−mice by immunoblot. We found no difference in mTOR
protein levels (Fig. 5A), but we observed a 2-fold increase in the nigral
levels of phosphorylated (Ser 2448) mTOR (pmTOR) in the En1+/−
mice (Figs. 5A and B). PmTOR, in turn, activates p70 S6 kinase. To
monitor pmTOR and pS6 levels speciﬁcally in the substantia nigra, we
performed immunohistochemistry and densitometric analyses. As
expected, we found that pmTOR and pS6 levels were increased in the
substantia nigra of the 16-week-old En1+/−mice (Figs. 5C and G). Con-
sistent also with the upregulation of pmTOR, we observed increased
(1.6-fold) phosphorylation (Ser 235/236) of S6, a downstream effectorof the mTOR pathway (Figs. 5E and F). In contrast, the total S6 level of
the En1+/− mice was not altered as compared to WT mice (Fig. 5E).
Double-immunohistochemical labeling for TH and pmTOR revealed an
accumulation of pmTOR in nigral dopaminergic neurons in the En1+/−
mice (Figs. 5C and D). Similarly, we observed increased expression of
pS6 in caudal midbrain sections of the En1+/− mice (Fig. 5G and H).
Taken together, these results suggest that the activation of mTOR
signaling pathway is upregulated in nigral dopaminergic neurons of
the En1+/−mice, implying that alterations in the mTOR-mediated reg-
ulation of autophagy might be involved in the degeneration of dopami-
nergic neurons. In order to determine whether the absence of one En1
allele also affected the expression of autophagic markers in the mid-
brain, we measured levels of the microtubule-associated protein light
chain 3 (LC3B) by immunoblots on protein extracts from ventral mid-
brain of the 16-week-old-mice (Fig. 5I). We found a reduction in both
forms of the protein, LC3B-I and LC3B-II, with a signiﬁcant decrease in
LC3B-II/LC3-I ratio inmidbrain of the En1+/−mice, indicative of a reduc-
tion in autophagosome formation (Fig. 5J). To monitor the presence of
autophagosomes in dopaminergic neurons,weperformed immunoﬂuo-
rescence co-labeling of LC3B and TH on 16 week WT and the En1+/−
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Fig. 4. Progressive distal degeneration of dopaminergic axons in En1+/−mice. A-B, Density of dopaminergic ﬁbers shown in max projection of 6 μm confocal stacks of immunolabeled
striatal sections from 8-week-old TH–GFP; En1+/− and TH–GFP; WT mice. TH–GFP; En1+/−mice display swollen dystrophic dopaminergic axon terminals that co-express (A) TH and
GFP, (B) VMAT2 and GFP, and (C) DAT and GFP. D, Orthogonal slice view of striatal section, immunolabeled with DAT and TH, from a 16-week En1+/− animal. DAT is located in the mem-
brane of the swollen terminal, whereas TH is located in the axoplasm. Scale bars A–D: 20 μm. E, Quantiﬁcation of the swollen TH-positive terminals of 8-day-, 4-week-, and 24-week-old
En1+/−mice revealed an increasing number with age (n= 4–5 animals/stage). F, G, TEM imaging of dorsal striatum from 8-week-oldWT and En1+/−mice. F, Representative image of a
WT control showing normal dendrites and synaptic components in the dorsal striatum. G, Image display abnormal enlarged axonal processes of various sizes in the striatum of En1+/−
mice. These axons accumulate electron-dense bodies (arrows), abnormal autophagolysosomes (dashed arrows) and abnormalmitochondria (arrowheads). Scale bar: 1 μm.H, TH-positive
ﬁbers in theMFB region of 8-week-old En1+/−mice showdisorganized and fragmentedmorphology, unlike those in theWTmice. Scale bar: 20 μm. I, TH-positive axonalﬁbers in 32-week-
old En1+/−mouse brain prepared by the CLARITY technique, showdiscontinuous structures, not seen inWT animals. Inset shows distinct breakage site along the axon. Scale bars: 20 μm;
inset scale bar: 5 μm.
75U. Nordström et al. / Neurobiology of Disease 73 (2015) 70–82midbrain sections (Fig. 5K). Quantiﬁcation of the intensity of LC3B
ﬂuorescence and the number of LC3B-immunoreactive punctae present
inside the nigral TH-positive neurons revealed that LC3B levels were
reduced in dopaminergic neurons in the En1+/−mice (Figs. 5L, M).
Impaired striatal dopamine neurotransmission in the En1+/− mice
In light of the changes in dopamine neuron markers in the striatum
of the young En1+/− mice and the early degeneration of nigrostriatal
terminals, we hypothesized that nigrostriatal pathway function isimpaired prior to the loss of nigral dopaminergic neurons. To test this
hypothesis, we used in vivo chronoamperometric recordings of
dopamine release and reuptake in the striatum of the WT and En1+/−
mice. Using an assembly of a carbon ﬁber for dopamine detection and
a glass capillary for local KCl administration, we measured dopamine
release and reuptake at six different positions (separated by 250 or
500 μm) along a tract running from the dorsal to the ventral striatum
(Fig. 6A, left panel). We found that the KCl-induced dopamine release
(Fig. 6B) and the subsequent dopamine reuptake (Fig. 6C) were similar
in the 4-week-old WT and En1+/−mice. In contrast, the 16-week-old
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mice immunostained for TH and pS6. Inset pictures demonstrate overlap of signal of TH and pS6. Scale bar: 50 μm. H, pS6 staining in the TH-positive cells (arbitrary units). I-J, immunoblot
analysis of LC3B-I and LC3B-II levels in lysates from 16-week-old WT and En1+/− substantia nigra, *p b 0.05, n= 3 for WT and En1+/− groups. K, Images of substantia nigra regions of
16-weekWT and En1+/−mice that have been ﬂuorescently colabeled for TH and LC3B. Scale bar, 50 μm(10×) and 20 μm(40×). L, Quantiﬁcation of the LC3B signal in TH-positive neurons
in the substantia nigra, *p b 0.05, n= 3 per group. M, Quantiﬁcation of distinct LC3B-labeled punctae in TH-positive neurons in the substantia nigra, ***p b 0.001, n= 3 per group.
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Fig. 6. En1+/−mice have reduced dopamine neurotransmission in the striatum. A, Left: Schematic image of striatal electrode insertion site, and positions 1–6 where KCl was injected
and the in vivo electrochemical recordings were done. Right: Circles represent the subregions of the striatum where punches were taken for HPLC analysis. B and D, graphs represent
means ± SEM values for estimated dopamine release in response to KCl stimulation. C and E, Graphs depict means ± SEM of Tc(80–20%), the rate at which dopamine was cleared from
the synaptic cleft. B–C, At 4 weeks of age, bothWT and En1+/− groups showed similar levels of (B) KCl-stimulated dopamine release and (C) synaptic clearance (reuptake) of dopamine.
D, KCl-induced releases of dopaminewere reduced at positions 1 and 2 of 16-week-old En1+/−mice relative to theWTmice. Themaximumamount of dopamine released is presented as
mean±SEM(with signiﬁcance after unpaired t-test: *pb 0.05, **p b 0.01). E, Dopamine reuptakewas altered at positions 1 and 2, displaying slower clearance rates in the 16-week En1+/−
group and signiﬁcant differences fromWTvalues (unpaired t-test; *p b 0.05, **p b 0.01). F, G,H, HPLC analysis of basal dopamine (F), DOPAC (G) and HVA (H) levels in subregions DM, DL,
M and V of 16-week-old WT mice (n= 12–14) and En1+/−mice (n= 10–11). Comparisons were made between En1+/− subregions (unpaired t-test: ns = non-signiﬁcant), and with
their respective WT subregion (unpaired t-test: *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001).
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in the dorsal striatum. In the two most dorsal recording positions
(positions 1 and 2 in Fig. 6A, left panel), the maximum amplitudes
of KCl-evoked dopamine release were reduced by 88% and 53%,respectively, in the En1+/−mice relative to WT (Fig. 6D). Furthermore,
in those positions, the En1+/−mice displayed a lower capacity to clear
extracellular dopamine, 95% lower at position 1 and 68% lower at posi-
tion 2 (Fig. 6E).
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regional reduction in local dopamine tissue levels. We measured the
tissue levels of dopamine and metabolites in four subregions of the
striatum: dorso-medial (DM), dorso-lateral (DL), mid (M) and ventral
(V), as shown in Fig. 6A, right panel. At 16 weeks of age, the En1+/−
mice showed a 26% reduction in the levels of dopamine in the striatum
overall. The reduction did not, however, differ signiﬁcantly between the
four subregions of the striatum (Fig. 6F). Thus, the dramatic reduction in
dopamine release in the dorsal striatum seen in our in vivo electro-
chemistry experiments could not be explained by an equivalent region-
al decrease in tissue levels of dopamine. Similarly, HVA levels in all
subregions of the En1+/− mice were reduced relative to WT controls,
but there were no differences among subregions within the En1+/−
striatum (Fig. 6H). In contrast, the tissue levels of DOPAC did not signif-
icantly differ between the mutant and WT mice for any of the striatal
subregions (Fig. 6G). Together, our results suggest that the neurotrans-
mission in the dopaminergic terminals is functionally impaired, speciﬁ-
cally in the dorsal striatum of the En1+/−mice.
Discussion
We found that early stages of progressive degeneration of nigrostriatal
system in the En1+/−mice are detectable in the axonal terminals, several
weeks before the loss of nigral dopaminergic neurons is evident. In
agreement with previous studies (Sonnier et al., 2007), we observed
that dopaminergic neurons were not lost during the ﬁrst 4 postnatal
weeks. However, as early as 8 days of age, we identiﬁed morphological
abnormalities (i.e. swollen axon terminals, so called spheroids) in the
nigrostriatal pathway consistent with axonal degeneration. These
changes persisted in the oldest mice we studied (32 weeks of age).
The abnormal axonal spheroids, at 16 weeks, were immunoreactive
for TH, VMAT2, and DAT suggesting that the degenerative process is
still at an early stage in the particular neurons that exhibit these axonal
changes. Analyses of markers for dopaminergic neurons in striatal tis-
sue samples provide additional evidence for changes occurring in
nigrostriatal terminals before the nigral neurons die. Thus, we found
that the total striatal levels of TH, dopamine, and DAT were decreased
before the number of nigral dopaminergic neurons was substantially
reduced in the En1+/− mice. Recent reviews on the development of
nigrostriatal pathology in PD have emphasized that striatal terminal
loss is an early neuropathological event in the disease (Burke and
O'Malley, 2013; Cheng et al., 2010). The notion that the pathology starts
in the terminal region is supported by a recent study in post-mortemPD
brains showing that nigrostriatal neurons exhibit dramatically reduced
TH and DAT immunostaining in the striatum as early as within 4–5 years
after onset of motor symptoms (Kordower et al., 2013). In contrast, the
loss of melanin-containing dopaminergic neurons in the substantia
nigra continues during the ﬁrst decade following PD diagnosis. In short,
those post-mortem ﬁndings in PD clearly agree with the idea that a loss
of function or degeneration of nigrostriatal terminals precedes cell death
in the substantia nigra (Kordower et al., 2013).
Earlier literature has proposed that a Wallerian-type axonal degen-
eration could be a common feature of several progressive neurodegen-
erative disorders (Coleman and Perry, 2002; Yamamoto and Yue, 2014).
Dystrophic axonal spheroids (rich in gamma-synuclein) have been
described in the PD hippocampus (Galvin et al., 1999). A recent report
suggesting that axonal transport fails in PD brain (Chu et al., 2012), sup-
ports the idea that axonal failure is an early feature of PD. Our results
using the CLARITY technique in the En1+/− mice clearly demonstrate
that individual axons in the nigrostriatal pathway undergo fragmenta-
tion, which suggests failure of axonal maintenance. Indeed, multiple
studies have reported that the En1 protein regulates axon growth and
maintenance (Stettler et al., 2012; Wizenmann et al., 2009; Yoon et al.,
2012). For example, En1 has been shown to stimulate axon growth
and guidance in the retina and tectum by interacting with EphrinA pro-
teins (Brunet et al., 2005; Wizenmann et al., 2009). The proposedmolecular mechanism involves the regulation of axonal translation
that is activated in the presence of En1 protein. Addition of En1, and
its internalization into the axons of cultured retinal ganglion cells,
leads to a rapid increase in translation of mitochondrial complex I pro-
teins (Ndufs1, 2, 3) in axons with concomitant increases in ATP levels
(Stettler et al., 2012). Another recent study showed that En1 regulates
axonal translation of the mRNA of the type V intermediate ﬁlament
lamin B2. Axonal Lamin B2promotesmitochondrial function and axonal
transport, and reduction in axonal lamin B2mRNA translation in retinal
ganglion cells leads to axonal degeneration (Yoon et al., 2012). Further
studies are needed to deﬁne if axonal translation and axonal transport
are impaired in nigrostriatal dopamine neurons in the En1+/−mice.
Mitochondrial dysfunction has been implicated as a major contribu-
tor to PD pathogenesis (Exner et al., 2012). Deﬁciencies in the complex I
subunit (both decreased activity and reduced protein levels) have been
detected in the PD substantia nigra, linking them to idiopathic PD
(Mizuno et al., 1989; Schapira et al., 1989, 1990). The En1+/− mouse
exhibits decreased levels ofmitochondrial proteins in themidbrain. Fur-
thermore, dopamine neurons from the En1+/−mice exhibit heightened
sensitivity to the neurotoxins 6-hydroxydopamine and MPTP, both of
which are suggested to act on mitochondria (Alvarez-Fischer et al.,
2011). Consistent with these observations, intracerebral infusions of
En proteins result in increased mitochondrial protein translation and
are neuroprotective in mitochondrial toxin-based models of PD in vivo
(Alvarez-Fischer et al., 2011).
Based on the literature and our own ﬁndings, we propose that
reduced En1 function initially causes energy failure in dopaminergic ter-
minals. Due to the extensive axonal arborisations, nigrostriatal neurons
have been suggested to be particularly susceptible to partial energy fail-
ure (Pissadaki and Bolam, 2013). A reduction in energy production,
coupled to impaired axonal transport and the accumulation of defective
mitochondria requiring clearance by mitophagy, leads to failure of
maintenance of dopaminergic axons, ﬁnally resulting in their disinte-
gration. The resulting stress on the cell body, as well as a potential re-
duction of target-derived trophic support (Jackson-Lewis et al., 2000),
lead to the eventual death of the neuron.
Recently, the concept that dopaminergic axons might undergo
macroautophagy in PD has been discussed extensively (Burke and
O'Malley, 2013). Compelling evidence suggests that neurodegeneration
in PD involves dysregulation of autophagy, e.g., autophagosomes and
protein aggregates have been observed in PD post-mortem brains
(Malagelada et al., 2010). Different models show that impaired autoph-
agy in dopaminergic neurons is coupled to aggregation of α-synuclein
(Pan et al., 2008), akin to the Lewy aggregates found in dopamine neu-
ron terminals in PD (Deleidi and Maetzler, 2012).
Upon the disrupted maturation of autophagosomes and the subse-
quent fusion to lysosomes, there is a buildup of immature autophagic
vacuoles (Yang et al., 2013). In our ultrastructural analysis, we found
that autophagic vacuoles accumulated in the En1+/− dopaminergic
terminals. The protein LC3B exists in a cytosolic form (LC3-I) and a
membrane-bound form (LC3-II), with the latter commonly used as a
marker for autophagosomes. The abundance of LC3-II protein is indica-
tive of the number of autophagosomes in a cell (Yamamoto and Yue,
2014). We found that LC3B levels are reduced in the ventral midbrain
of the En1+/− mice. Furthermore, our immunohistochemical analysis
at the cellular level revealed that the soma of the En1+/− dopaminergic
neurons display a reduction in LC3B-immunoreactive punctae, sugges-
tive of reduced autophagy in these cells. Using our immunohistochem-
istry protocol, we did not detect LC3B in the dopaminergic terminals in
the striatum. However, our ultrastructural observations suggest that
autophagic degradation is defective in the nigrostriatal terminals of
the En1+/−mice.
The mammalian target of rapamycin (mTOR) pathway, which nor-
mally acts by inhibiting autophagy mechanisms responsible for degra-
dation and clearance of proteins, has also been directly implicated in
PD (Burke and O'Malley, 2013; Laplante and Sabatini, 2012). Inhibition
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and animal-models of PD (Malagelada et al., 2010). Rapamycin can also
increase lysosomal levels in and attenuate death of dopaminergic neu-
rons in another cell culture model of PD (Dehay et al., 2010). In the
present study, we observed an up-regulation of pmTOR and its target
molecule pS6 inside the dopaminergic neurons of the En1+/− mice.
This suggests that an imbalance in protein degradation contributes to
the degeneration of the nigral En1+/− dopaminergic neurons, adding
further validity to the En1+/−mouse as a PD model.
Our ﬁndings suggest that the loss of one En1 allele causes a function-
al decline in the subpopulation of dopaminergic neurons that primarily
projects into the dorsal striatum. The recent work using a single cell
analysis of gene expression has shown that gene expression patterns
vary signiﬁcantly among midbrain dopaminergic neurons in postnatal
mice (Poulin et al., 2013). Interestingly, the transcript levels for En1
and En2 (which encodes a protein that has some overlapping functions
with En1) are lower in the ventral substantia nigra relative to several
other dopamine neuron populations in the nigra and ventral tegmental
area of theWTmice (Poulin et al., in press). En proteins are not present
at similar levels throughout the substantia nigra of adult mice. Whereas
En1 expression is widespread throughout the substantia nigra, En2 is
only expressed in a subset of nigral neurons. However, En2 transcript
level was boosted in the substantia nigra of the En1-null mice and
seems to compensate for loss of En1 function. To better understand
the role of redundancy of En proteins, and selective vulnerability, it
will be important to characterize the distribution and expression of
En1 and En2 transcripts and proteins in subregions of the substantia
nigra of the adult En1+/−mice. It is also possible that different subsets
of midbrain dopaminergic neurons differ in their dependence on En1.
For example, Veenvliet and colleagues have found that in En1-null em-
bryos, TH and DAT are decreased in the rostrolateral region of the mid-
brain but are not altered in the caudal midbrain (Veenvliet et al., 2013).
Further studies are needed to deﬁne thedifferential vulnerability of sub-
sets of midbrain dopaminergic neurons to degeneration following re-
ductions of En1 protein and to deﬁne whether the most susceptible
nigral neurons are analogous to those that degenerate ﬁrst in PD.
Our results also revealed a striking defect in striatal dopamine neu-
rotransmission in the En1+/−mice. In the dorsal striatum of 16-week-
old mice (but not 4-week-old mice), we observed a 88% reduction in
evoked dopamine release and a 95% reduction in clearance of extracel-
lular dopamine by DAT. Reductions in DAT function are also a feature
of early PD, as demonstrated using DAT-SPECT (Kagi et al., 2010). The
striatal tissue level of dopamine was also reduced in the En1+/−mice
at the same age. This reduction was, however, modest (around 26%)
and could not explain the severe changes in dopamine neurotransmis-
sion that we observed. The overexpression of α-synuclein in PD mouse
models suggests that accumulation of α-synuclein impairs dopamine
neurotransmission by reducing vesicle load and reducing dopamine re-
lease and reuptake (Hansen et al., 2013; Lundblad et al., 2012). We did
not observe any obvious α-synuclein accumulation or aggregates in the
En1+/−mice (data not shown). Thus, α-synuclein accumulation and/or
aggregation do not seem to explain the deﬁcits in dopamine neurotrans-
mission in this PD model. Indeed, the En1 double-null mice reportedly
show decreased α-synuclein levels in midbrain dopaminergic neurons,
suggesting that En1 normally would enhance α-synuclein levels, possi-
bly as part of a process regulating axon growth (Simon et al., 2001).
En1 protein is required for the speciﬁcation and maturation of
dopaminergic neurons during development (Simon et al., 2001). The
observation that the En1+/−mouse exhibits a full quota of nigral dopa-
minergic neurons at birth, and initially displays normal dopamine
signaling, excludes dopaminergic loss due to a developmental effect.
In concordance with other proteins (e.g. Pitx3 and Nurr1) that govern
dopaminergic neuron development together with En1, the expression
of En1 continues during adulthood (Simon et al., 2001) and is required
for the maintenance of axonal integrity and dopaminergic neuron
survival. Interestingly, mutations in the Nurr1 and Pitx3 genes alsoassociate to PD (Fuchs et al., 2009; Le et al., 2003). Similarly to the
En1+/−mice, conditional knockout mice where Nurr1 is ablated in do-
paminergic neurons during adulthood exhibit progressive dopaminer-
gic neuron pathology, show progressive development of TH-positive
dystrophic dendrites, and reduction of striatal dopamine (Decressac
et al., 2012; Kadkhodaei et al., 2013).
In conclusion, we report that the loss of En1 function in the mice
causes axonal degeneration that precedes dopamine cell death. Several
features we have observed suggest that the nigrostriatal axons die back
slowly, causing eventual nigral cell death in a process involving autoph-
agy. An important additional characteristic of our mouse model is
severe impairment in dopamine neurotransmission in the dorsal stria-
tum. The protracted course of axonal degeneration and nigral cell
death in the En1+/− mouse already makes it very suitable for studies
on potential neuroprotective agents. In the future, it will be useful to ex-
plore how the degeneration of the nigrostriatal pathway in the En1+/−
mice responds to situations when α-synuclein levels are elevated
experimentally.
Materials and methods
Animals
Themicewere treated in accordancewith theGuide for the Care and
Use of Laboratory animals (US National Institutes of Health) and with
approval of the VanAndel Research Institute's IACUC. The En1 heterozy-
gous mice were generated as described earlier and were maintained on
an OF1 genetic background (Sonnier et al., 2007). They express the LacZ
gene downstream of the En1 promoter, which drives the expression of
β-galactosidase (β-gal). The mutant TH–GFPmice were also generated
as described above and maintained on a C57BL-6J genetic background
(Sawamoto et al., 2001). The TH–GFP mutant mice were backcrossed
at least eight generations to OF1 mice, before being crossed with the
En1+/−mice to generate the double mutant TH–GFP; En1+/− animals.
Immunohistochemistry (IHC)/immunoﬂuorescence (IF)
The mice were anesthetized with pentobarbital and perfused intra-
cardially with 4% paraformaldehyde (PFA). Intact brains were removed
and post-ﬁxed overnight in the PFA solution before being equilibrated
in 30% sucrose. Brains were serially (6) sectioned into 30- to 40-μm-
thick coronal and sagittal sections for IF and IHC.
For TH IHC, free-ﬂoating sections were washed with 0.1 M PBS
(pH 7.4), incubated with 3% H2O2 for 10 min to quench endogenous
peroxidase activity, and were blocked for 1 h with 10% normal goat
serum and 0.25% Triton X-100. Next, the sections were incubated
overnight at 4 °C with the TH primary antibody (1:1500, Pel-freez Bio-
logicals, USA). The next day, the sections were washed with 0.1% Triton
X in PBS and incubated with a biotinylated goat anti-rabbit secondary
antibody (1:500, Vector Laboratories, USA) for 1 h at room temperature.
The intensity signal was then ampliﬁed by incubating the sections with
the Avidin/Biotin ABC reagent (Vector Laboratories, USA). Finally, the
immunostaining was revealed by incubation with the chromogen di-
aminobenzidine (DAB), producing a brown color visible in bright-ﬁeld
light microscopy. Sections were dehydrated in increasing ethanol
concentrations, cleared in xylene, and mounted on slides using DPX
medium (Electron Microscopy Sciences, USA).
For double-labeling IF, the H2O2 quenching step was omitted and
the sectionswere directly blockedwith normal goat serum before incu-
bation overnight at 4 °C with the following primary antibodies: TH
(1:1500, Pel-freez Biologicals, USA); GFP (1:500, Abcam, USA); β-gal
(1:500, Abcam, USA); TH (1:1500, Chemicon, USA); p-mTOR (1:200,
Cell signaling, USA); p-S6 (1:400, Cell signaling, USA); LC3B (1:500,
Cell signaling, USA) or En1/2 (1:1000, produced in Alain Prochiantz's
laboratory). The secondary antibodies goat anti-rabbit and goat anti-
mouse coupled to Alexa 488 or 594 (1:500, Jackson ImmunoResearch,
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sections were mounted with ProLong Gold antifade medium (Life
Technologies, USA) and coverslipped. Sections were viewed under a
NIKON eclipse Ni-U ﬂuorescence microscope (Nikon, USA); images
were captured with a Retiga Exi digital camera using NIS Elements AR
4.00.08 software (Nikon, USA). Confocal imaging was performed with
a Nikon Eclipse Ti-E inverted microscope (Nikon, USA), followed by
deconvolution techniques using Huygens software (Scientiﬁc Volume
Imaging, USA).
Measurement of ﬂuorescence intensity and densitometry
A total of two sections per brain containing the substantia nigra
region and threemice per groupwere stainedwith antibodies direct-
ed against TH, pmTOR, pS6, and LC3B as mentioned above. After im-
munoﬂuorescence or histochemical staining, four 40× images were
taken from each section and the mean intensity of ﬂuorescence of
pmTOR, pS6, LC3B, and TH in TH-positive neurons, as well as counting
of LC3B immunoreactive punctae in TH-positive neurons in substantia
nigra were quantiﬁed using NIS Elements AR 4.00.08 software (Nikon,
USA).
CLARITY
Thirty-two-week-old WT and En1+/−mice were perfused with hy-
drogel monomers solution, as described earlier (Chung et al., 2013).
The brains were extracted and stored in the hydrogel monomers so-
lution for 3 days at 4 °C, followed by hydrogel tissue embedding at
37 °C for 3 h. The brain hemispheres were separated and processed
individually. The samples were incubated in a clearing solution
(which contained sodium borate buffer [200 mM (pH 8.5) and 4%
SDS]), at 37 °C with gentle rotation for 5–6 weeks. Once the samples
were clariﬁed, they were washed for 2 days with PBS plus 0.1% Triton
X (PBS-T).
For TH immunostaining, clariﬁed brain samples were incubated at
37 °C with gentle rotation for one week with the primary antibody
(1:50, Calbiochem, USA) diluted in PBS-T, followed by 3 days of washes
with PBS-T at 37 °C. The samples were then incubated with the second-
ary antibody, goat anti-rabbit coupled to Alexa 594 (1:200, Jackson
ImmunoResearch, USA) diluted in PBS-T, at 37 °C for one week;
then they were washedwith PBST at 37 °C for 3 days. Before confocal
imaging, samples were mounted on coverglass-bottomed dishes
(Willco) with FocusClear (CelExplorer) and allowed to equilibrate
overnight at room temperature. The clariﬁed samples were then im-
aged using an inverted Nikon A1-RSi confocal microscope with a
10X, 0.3 NA air objective and a 20×, 0.75 NA multi-immersion objec-
tive with 85% glycerol lens immersion. Image stacks were acquired
with a Z-step spacing of 0.85 μm. The lateral and axial imaging resolu-
tion was determined by a Nyquist sampling calculator, and all images
were deconvolved using Huygens Pro (Scientiﬁc Volume Imaging,
Netherlands).
Stereological estimation of dopaminergic neurons in the substantia nigra
The dopaminergic neurons of theWT and En1+/− micewere identi-
ﬁed after TH DAB staining of midbrain regions with a 2× objective and
the substantia nigra region was outlined based on the Allen mouse
brain atlas. Quantitative estimation of TH-positive neurons was per-
formed in every 6th section of the substantia nigra. Brieﬂy, the unbiased
sampling and blinded stereological counting were done using the opti-
cal fractionator probe in Stereo Investigator software (MBF Bioscience,
USA). The parameters used include a 60× oil objective, a counting
frame size of 60 × 60, a sampling site of 100 × 100, a dissector height
of 12 μm, 2 μmguard zones and the Schmitz-Hof's second estimated co-
efﬁcient error less than 0.1. A total of 6 to 7 animals per groupwere used
and 5 to 8 sections per animal were counted.Quantiﬁcation of the TH-positive dystrophic terminals
After TH immunostaining of 40-μm-thick striatal sections, one
section per mouse (n = 4–5 animals per group) at position bregma
0.7–0.9 mm (Paxinos mouse atlas) was imaged with a 40× objective
covering in average 10 ﬁelds of view in the striatum. Automated
counting of degenerating proﬁles was performed using the Image J
plugin “Analyze particles” for a total of 38–45 sampling sites of
375 μm×375 μm in size. Formorphological criteria of insertion, positive
dystrophic terminalswere thresholded for aminimum size of 3 μm2 and
a circularity index of N0.8. By setting the parameters, we ensured that
segmented degenerating proﬁles were counted without counting
axons or dendrites.
In vivo electrochemistry
Highspeed chronoamperometric recordings were made using FAST-
16mkII software and hardware (Quanteon, L.L.C. Nicholasville, KY, USA)
ﬁttedwith carbon ﬁber electrodes (ﬁber diameter 30 μm; exposed length
120–150 μm, type SPF1a, Quanteon, USA) as previously described in
(Lundblad et al., 2012). In short, a square wave potential was applied
(+0.55V; resting 0.0 V vs. Ag/AgCl reference) and the resulting oxidation
and subsequent reduction currents collected by the carbon ﬁber elec-
trodes were integrated during the ﬁnal 80% of each 100-ms pulse. Oxida-
tion and reduction currents were continually recorded and integrated
over 0.5 s (2 Hz recording). Electrodes were then dried in dry oven at
200 °C, dipped 1 s in 5% Naﬁon (Sigma, Sweden), and placed back in
oven at 200 °C for 5min. This procedurewas repeated three times. Naﬁon
coating was used to prevent detection of anionic substances and thus in-
crease the sensitivity for dopamine. Each electrode was calibrated indi-
vidually against ﬁxed 2 μM increments of dopamine in 0.1 M PBS
solution (pH 7.4) at room temperature. Selectivity against ascorbic acid
was determined as the ratio of oxidation current response to ascorbic
acid and dopamine. Limit of detection was less than 47 nM for all elec-
trodes used, linearity of response was r2 N 0.998 and selectivity was
greater than 339:1 for dopamine against ascorbic acid.
Each electrode was ﬁtted with a glass capillary (outer diameter
20–25 μm) connected to a micropressure system (Parker Picospritzer
III, Aldax, Sweden) for local application of 100–120 nl KCl (120 mM).
The distance between the tip of the electrode and the tip of the glass
capillary was set to 90–110 μm and the ejected KCl volume was deter-
mined bymovement of themeniscus in the glass capillary andmeasured
using a stereo microscope ﬁtted with a reticule. An Ag/AgCl electrode
used as a reference electrode in vivo was prepared by electroplating a
Ag wire in 1 M HCl solution saturated with NaCl for at least 30 min.
Recordings were made bilaterally from striatum from all animals at
the coordinates AP: +0.5 mm; L: ±2.0 at 6 different depths. To enable
measurement from the most dorsal part of striatum, KCl was ejected at
−1.5 mm DV coordinate and moved down 250 μm until dopamine
release (peak amplitude N0.2 μM) was obtained. The ﬁrst dopamine re-
lease depth (peak amplitude N0.3 μM)was considered the ﬁrst in the se-
ries of 6 depth coordinates. From the ﬁrst coordinate in the striatum the
electrode was lowered in three 250-μm increments and then two
increments of 500 μm.
Recordings were made at 4 or 16 weeks of age for the WT and En1+/–
mice. The animals were anesthetized using isoﬂurane anesthesia (4% in in-
duction chamber, 1.5% in the stereotaxic frame throughout the recording
session) and positioned in a stereotaxic frame. Body temperature was
maintained at 37 °C with a constant temperature heating pad connected
to a thermostatically controlled water pump (Micro-Temp LT, USA). The
skull anddurawere removedbilaterally above the recording sites. The elec-
trode/glass capillary assembly was lowered into the brain to the ﬁrst re-
cording coordinate using a micromanipulator (Narishige MO-10, Japan)
and left for at least 30 min to provide a baseline. A ﬁxed volume of KCl
(100 nl ± 10 nl) was ejected at each recording position. Data from the
two hemispheres were averaged on each recording point. Due to technical
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spheres (En1+/−4-week group: 3 animals;WT16-week group: 2 animals).
All parameters of the amperometric datawere calculated using FAST
analysis version 4.0 for Mac (Quanteon LLC, USA). Peak amplitude was
calculated as the difference of (maximum dopamine concentration
after KCl injection)–(baseline prior to KCl injection). Clearance (Tc) is
deﬁned as the linear rate of concentration decrease (μM/s) between
T60 (time when signal amplitude is 60% of peak amplitude) and T40
(time when signal amplitude is 40% of peak amplitude).
Immunoblots
The animals were euthanized by rapid decapitation, and brainswere
then quickly removed and dissected to collect striata and substantia
nigra regions. The tissues were stored at−80 °C until use. Total pro-
teins were extracted in RIPA buffer supplemented with protease inhib-
itor cocktail (Sigma, USA), phosphatase inhibitors (3 mM sodium
pyrophosphate, 10mM sodium ﬂuoride, 2 mM sodium orthovanadate),
and 1 mM PMSF. The lysates were centrifuged at 15 000 × g for 20 min
at 4 °C and the supernatants were used in immunoblotting. After pro-
tein quantitation (BCA assay kit, Pierce, USA), proteins were separated
by SDS-PAGE using 4–15% gradient gels (Biorad, USA) and transferred
to nitrocellulose membrane. Blots were blocked with 5% dry milk dilut-
ed in 0.1 M TBS/0.1% Tween-20 and were incubated overnight at 4 °C,
with primary antibodies [TH, 1:1500, Pel Freez Biologicals, USA; DAT,
1:1000; pmTOR (Ser2448), 1:1000; mTOR, 1:1000; pS6 ribosomal pro-
tein (Ser235/236), 1:1000; S6 ribosomal protein, 1:2000; LC3B, 1:1000,
Cell Signaling, USA] diluted in a solution of 0.1MTBS, 0.1% Tween-20, 5%
BSA. Incubations with secondary antibodies goat-anti-rabbit IgG (H&L)
IRDye® 800 Conjugated (1:10000, Rockland, USA) and Alexa Fluor
680 goat anti-mouse IgG (H + L) (1:10000, Invitrogen, USA) were per-
formed in blocking solution for 1 h at room temperature. Band detection
was performed using the Licor Odyssey system and quantiﬁed using
Image J software. Later, blots were stripped with the Restore Western
Blot Stripping Buffer (Thermo Scientiﬁc, USA) and reblotted for β-Actin
(1:10000, Abcam, USA).
Transmission electron microscopy
The mice were perfused with 2.5% glutaraldehyde/4% PFA in 0.1 M
sodium cacodylate buffer. Using a vibratome, 1-mm3 blocks were cut
from the dorsal lateral striatum and post-ﬁxed for at least 24 h. The
tissues were then processed through various treatments that revealed
contrast between cellular compartments. The sections were ﬁrst
incubated in more specialized ﬁxative solutions. They were then post-
ﬁxed in 0.1% tannic acid for 1 h at room temperature. After washes
with 0.1 M cacodylate buffer, the samples were incubated with the sec-
ond post-ﬁxative solution containing osmium tetroxide and potassium
ferrocyanide at room temperature for 2 h. Then, the samples were
ready to be stained and were ﬁrst treated for 30 min with a solution
of thiocarbohydrazide, which deposited an opaque layer of electrons
to increase membrane contrast. The second staining step was incubation
with 2% osmium tetroxide for 60 min at room temperature, which also
increased contrast of extracellular compartments.
Next, sections were incubated overnight at 4 °C with the primary
stain solution of 1% uranyl acetate, a heavymetal salt that stains nucleic
acids and proteins. Afterwashingwithwater, the sectionswere incubat-
edwith the secondary stain, lead aspartate, to increase intracellular con-
trast. Next, the sections went through a series of incubation steps of
increasing ethanol concentrations (50, 75, 85, 95, 100%), followed by a
ﬁnal wash with propylene oxide. The samples were embedded with
the Epon resin (following the manufacturer's instructions; EMbed-812
embedding kit, Electron Microscopy Sciences, USA) and propylene
oxide at a ratio of 1:1 overnight at room temperature. The following
day, the sections were transferred to fresh concentrated epon solution
and incubated for 90 min. The last steps of the staining process consistof mounting of the sections in a mold full with epon and curing at
60 °C for 48 h.
Serial blockface images (80 nm thick slices) were obtained with a
Zeiss Sigma VP scanning electron microscope equipped with a Gatan
3View in-chamber ultramicrotome, at a resolution of 5 nm per pixel.
The analysis of the images and annotationwere performedwith ImageJ.
HPLC
Extracellular dopamine and its metabolites were measured by our
previously published HPLC technique (Spieles-Engemann et al., 2010)
on either the entire striatum tissue (caudate and putamen regions) or
on micropunches from different striatal subregions. The micropunches
were dissected from the tissue at a 1-mm diameter. Next, the samples
to analyze were homogenized in an antioxidant buffer (0.4 N perchlo-
rate, 1.343mMEDTAand 0.526mMsodiummetabisulﬁte). After centri-
fugation, a fraction of the supernatants containing the cytoplasmic
proteins was run on the HPLC machine, while another fraction was
used to assess protein concentration. A Microsorb MV C-18 column
(5 Am, 4.6_250 mm, Varian, Walnut Creek, CA) was used to separate
the neurotransmitter from its metabolites, which were detected
using a 12-channel coulometric array detector (CoulArray 5200,
ESA, Chelmsford, MA) attached to a Waters 2695 Solvent Delivery
System (Waters, Milford, MA) under the following conditions: ﬂow
rate of 1 ml/min; detection potentials of 50, 175, 350, 400 and
525 mV; and scrubbing potential of 650 mV. The mobile phase was
10% methanol containing 21 g/L (0.1 M) citric acid, 10.65 g/L
(0.075 M) Na2HPO4, 176 mg/L (0.8 M) heptanesulfonic acid, and
36 mg/L (0.097 mM) EDTA at a pH of 4.1. Dopamine, DOPAC, and
HVA levels were normalized to the amounts of proteins and reported
as “ng/mg protein”.
Statistical analysis
Statistical analyses were calculated using GraphPad Prism, version
6.0d. For comparisons between theWTand En1+/− groups for immuno-
blot band intensities, stereological counting, ﬂuorescence intensity, and
HPLC data analyses, p values were determined after statistical unpaired
t-testswere performed, followed byWelch's correction. For establishing
the effects of genotype and anatomical region on in vivo electrochemis-
try and HPLC data from striatal punches, as well as genotype and age
effects on stereological quantitation of TH-positive neurons, protein
levels of TH and DAT, and counting of axonal swellings, we performed
two-factor ANOVA analyses, followed by Tukey's multiple comparison
tests.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2014.09.012.
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